B40.1 Chronic pulmonary blastomycosis

Name of the Condition

• Chronic pulmonary blastomycosis

Summary

Chronic pulmonary blastomycosis is a fungal infection of the lungs caused by Blastomyces dermatitidis (and related species). It results from inhaling airborne spores of the fungus, which convert to yeast in the lungs and may cause persistent or progressive respiratory disease. The condition typically presents with chronic respiratory symptoms and can lead to complications if left untreated, particularly in immunocompromised individuals.

Causes

The infection is caused by inhaling spores of Blastomyces fungi, which are found in soil and decaying organic matter in endemic regions. The spores germinate in the lungs, where they multiply and may spread to other organs via the bloodstream. Direct inoculation through skin wounds is rare.

Risk Factors

• Residence in or travel to endemic areas (e.g., parts of North America, particularly the Ohio and Mississippi River valleys).
• Occupational or recreational exposure to soil (e.g., construction, forestry, gardening).
• Immunocompromised states (e.g., HIV/AIDS, organ transplantation, chronic steroid use).
• Male gender (higher incidence reported).
• Advanced age.

Symptoms

• Pulmonary: Persistent cough (productive or non-productive), chest pain, dyspnea, fever, night sweats, weight loss.
• Systemic: Fatigue, myalgia, arthralgia.
• Disseminated disease may involve skin, bones, or central nervous system.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., chest X-ray or CT), and laboratory testing. Sputum or tissue samples may be examined for fungal elements, cultured, or tested via molecular methods (e.g., PCR). Histopathology of affected tissue can confirm the presence of Blastomyces yeast forms. Serologic tests may also be used but have limitations in sensitivity and specificity.

Treatment Options

Treatment typically involves antifungal medications, such as itraconazole or amphotericin B, depending on disease severity and patient factors. Mild to moderate cases may be treated with oral itraconazole, while severe or disseminated disease often requires initial therapy with amphotericin B followed by itraconazole. Duration of treatment varies based on clinical response and immune status.

Prognosis and Follow-Up

Prognosis is generally favorable with appropriate antifungal therapy, though recovery may be prolonged. Follow-up monitoring includes clinical assessment and repeat imaging or laboratory testing to ensure resolution of infection. Immunocompromised patients or those with disseminated disease may require longer treatment and closer surveillance.

Complications

• Respiratory failure or chronic lung damage.
• Dissemination to other organs (e.g., skin, bones, central nervous system).
• Recurrence of infection, particularly in immunocompromised individuals.

Lifestyle & Prevention

• Avoid exposure to soil or decaying organic matter in endemic areas, especially during activities that disturb the ground (e.g., gardening, construction).
• Wear protective respiratory equipment (e.g., masks) in high-risk environments.
• Maintain overall health to support immune function.

When to Seek Professional Help

Seek medical attention if you experience persistent respiratory symptoms (e.g., cough, chest pain, fever) or unexplained weight loss, especially if you live in or have traveled to an endemic region. Prompt evaluation is important for early diagnosis and treatment.

Tips for Medical Coders

Document the clinical presentation, diagnostic findings, and treatment plan to support coding for chronic pulmonary blastomycosis. Ensure documentation specifies the chronic nature of the pulmonary infection and any associated complications or risk factors. Verify that the code B40.1 is appropriate based on the patient's condition and avoid using this code for acute or disseminated forms of blastomycosis.